Last reviewed · How we verify
Celecoxib Oral Product
Celecoxib selectively inhibits cyclooxygenase-2 (COX-2), reducing the production of prostaglandins that mediate inflammation and pain.
Celecoxib selectively inhibits cyclooxygenase-2 (COX-2), reducing the production of prostaglandins that mediate inflammation and pain. Used for Rheumatoid arthritis, Osteoarthritis, Acute pain.
At a glance
| Generic name | Celecoxib Oral Product |
|---|---|
| Also known as | COX II Inhibitor |
| Sponsor | Ferring Ventures Limited |
| Drug class | Selective COX-2 inhibitor (coxib) |
| Target | COX-2 (Cyclooxygenase-2) |
| Modality | Small molecule |
| Therapeutic area | Rheumatology / Pain Management |
| Phase | Phase 3 |
Mechanism of action
As a selective COX-2 inhibitor, celecoxib preferentially blocks COX-2 while sparing COX-1, which is responsible for protective gastrointestinal and renal functions. This selectivity was designed to provide anti-inflammatory and analgesic effects with a reduced risk of gastrointestinal ulceration compared to non-selective NSAIDs. The drug is used to treat inflammatory conditions and pain by decreasing prostaglandin-mediated inflammation.
Approved indications
- Rheumatoid arthritis
- Osteoarthritis
- Acute pain
- Ankylosing spondylitis
- Familial adenomatous polyposis (FAP)
Common side effects
- Gastrointestinal disorders (dyspepsia, abdominal pain)
- Headache
- Hypertension
- Cardiovascular events (myocardial infarction, stroke)
- Edema
Key clinical trials
- I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients (PHASE2)
- TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy (PHASE2)
- Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer (PHASE2)
- Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors (PHASE2)
- Clinical Efficacy and Safety of Tender Point Infiltration (TPI) for Acute and Subacute Zoster Associated Pain (NA)
- Enhanced Recovery After Surgery in Orthopaedic Spine Surgery (PHASE2, PHASE3)
- Impact of Preoperative Opioid-free Multimodal Analgesia on Time to Trial of Void in Ambulatory Urogynecologic Surgeries (PHASE4)
- Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Celecoxib Oral Product CI brief — competitive landscape report
- Celecoxib Oral Product updates RSS · CI watch RSS
- Ferring Ventures Limited portfolio CI